Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA:600329)

SHA:600329 Revenue

Tianjin Pharmaceutical Da Ren Tang Group Corporation had revenue of 1.52B CNY in the quarter ending March 31, 2026, with 4.12% growth. This brings the company's revenue in the last twelve months to 4.98B, down -25.45% year-over-year. In the year 2025, Tianjin Pharmaceutical Da Ren Tang Group Corporation had annual revenue of 4.92B, down -32.70%.

• Revenue (ttm): 4.98B
• Revenue Growth: -25.45%
• P/S Ratio: 5.70
• Revenue / Employee: 1.28M
• Employees: 3,890
• Market Cap: 28.38B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	4.92B	-2.39B	-32.70%
Dec 31, 2024	7.31B	-915.58M	-11.14%
Dec 31, 2023	8.22B	-26.94M	-0.33%
Dec 31, 2022	8.25B	1.34B	19.42%
Dec 31, 2021	6.91B	303.89M	4.60%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

May 17, 2026

Data Sources Report a data error